NO330954B1 - Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose. - Google Patents

Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose.

Info

Publication number: NO330954B1
Authority: NO; Norway
Prior art keywords: sarcoidosis; treatment; peptides; medicament; treating
Prior art date: 2002-06-10

Application number

NO20040488A

Other languages

English (en)

Norwegian (no)

Other versions

NO20040488L (no

Inventor

Dorian Bevec

Original Assignee

Mondobiotech Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-10

Filing date

2004-02-03

Publication date

2011-08-22

2004-02-03 Application filed by Mondobiotech Ag filed Critical Mondobiotech Ag

2004-04-07 Publication of NO20040488L publication Critical patent/NO20040488L/no

2011-08-22 Publication of NO330954B1 publication Critical patent/NO330954B1/no

Links

201000000306 sarcoidosis Diseases 0.000 title abstract 4
239000003814 drug Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 2
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 2
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
229940126585 therapeutic drug Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Zoology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20040488A 2002-06-10 2004-02-03 Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose. NO330954B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02012767		2002-06-10
PCT/CH2003/000357 WO2003103702A1 (en)	2002-06-10	2003-06-05	Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis

Publications (2)

Publication Number	Publication Date
NO20040488L NO20040488L (no)	2004-04-07
NO330954B1 true NO330954B1 (no)	2011-08-22

Family

ID=29724383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040488A NO330954B1 (no)	2002-06-10	2004-02-03	Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose.

Country Status (13)

Country	Link
US (2)	US20060241028A1 (de)
EP (1)	EP1515745B1 (de)
JP (1)	JP2005535607A (de)
CN (2)	CN1313149C (de)
AT (1)	ATE425763T1 (de)
AU (1)	AU2003236072B2 (de)
BR (1)	BR0305039A (de)
CA (1)	CA2488358A1 (de)
DE (1)	DE60326723D1 (de)
DK (1)	DK1515745T3 (de)
HK (1)	HK1080363B (de)
NO (1)	NO330954B1 (de)
WO (1)	WO2003103702A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004255379B2 (en)	2003-07-14	2007-08-16	Mondobiotech Ag	Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
US7595294B2 (en) *	2004-10-08	2009-09-29	Transition Therapeutics, Inc.	Vasoactive intestinal polypeptide pharmaceuticals
WO2007073486A2 (en)	2005-12-20	2007-06-28	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) *	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
CN101434649B (zh) *	2008-12-12	2012-04-25	余榕捷	一种环七肽及其制备方法和应用
US9029505B2 (en)	2009-08-14	2015-05-12	Phasebio Pharmaceuticals, Inc.	Modified vasoactive intestinal peptides
CA2873553C (en)	2011-06-06	2020-01-28	Phasebio Pharmaceuticals, Inc.	Use of modified vasoactive intestinal peptides in the treatment of hypertension
US11052132B2 (en)	2014-05-08	2021-07-06	Phasebio Pharmaceuticals, Inc.	Methods and compositions for treating cystic fibrosis
CN114652817B (zh)	2015-02-09	2026-04-17	费斯生物制药公司	用于治疗肌肉疾病和病症的方法和组合物
US12411144B2 (en) *	2017-03-22	2025-09-09	Children's Hospital Medical Center	Compositions and methods for treatment of lung function
EP3583933A1 (de)	2018-06-20	2019-12-25	Albert-Ludwigs-Universität Freiburg	Verabreichung von aviptadil durch inhalation zur behandlung von chronischer berylliumkrankheit
CA3138891A1 (en)	2019-05-07	2020-11-12	Advita Lifescience Gmbh	Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis
CN115066254A (zh) *	2020-01-31	2022-09-16	阿德维塔生命科学有限责任公司	用于吸入治疗炎症性肺病的人抗炎肽
US20230381280A1 (en)	2020-12-04	2023-11-30	Centurion Ilaç Sanayi Ve Ticaret Anonim Sirketi	New dosage regimen for inhaled vasoactive intestinal polypeptide
WO2022224172A1 (en) *	2021-04-20	2022-10-27	Advita Lifescience Ag	Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3898329A (en) *	1971-09-17	1975-08-05	Sami I Said	Vasoactive intestinal peptide, composition and method
US3880826A (en) *	1971-09-17	1975-04-29	Sami I Said	Vasoactive intestinal peptide
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4237046A (en)	1979-04-27	1980-12-02	Miklos Bodanszky	Polypeptides and methods of preparation
GB8427651D0 (en)	1984-11-01	1984-12-05	Beecham Group Plc	Compounds
US4745100A (en)	1985-05-14	1988-05-17	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion
GB8525852D0 (en)	1985-10-19	1985-11-20	Beecham Group Plc	Compounds
GB8729802D0 (en)	1987-12-22	1988-02-03	Beecham Group Plc	Novel compounds
SE8705139D0 (sv)	1987-12-23	1987-12-23	Trion Forskning & Utveckling	Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5141924A (en)	1989-06-30	1992-08-25	Hoffmann-La Roche, Inc.	Synthetic vasoactive intestinal peptide analogs
JPH04193896A (ja)	1989-10-26	1992-07-13	Meiji Seika Kaisha Ltd	活性ペプチド
DE69101187T2 (de)	1990-06-26	1994-09-29	Sanwa Kagaku Kenkyusho Co	VIP-Analogen und ihre Verwendung.
AU656230B2 (en)	1991-10-11	1995-01-27	F. Hoffmann-La Roche Ag	Cyclic vasoactive peptides
JPH06220090A (ja)	1993-01-22	1994-08-09	Sanwa Kagaku Kenkyusho Co Ltd	ポリペプチド
IL105061A (en) *	1993-03-16	2000-11-21	Yeda Res & Dev	Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof
JPH07173197A (ja)	1993-12-20	1995-07-11	Sanwa Kagaku Kenkyusho Co Ltd	ポリペプチド修飾化合物及びその用途
JPH10502333A (ja)	1994-04-07	1998-03-03	プロティーンニックスカンパニー	バソアクティブ・インテスティナル・ポリペプチド
CN1186355C (zh)	1996-02-09	2005-01-26	霍夫曼-拉罗奇有限公司	血管活性肠肽类似物的合成
EP0914094A4 (de)	1996-03-28	2000-03-01	Univ Illinois	Materialen und verfahren zur herstellung verbesserter liposomaler mittel
EP0985671B1 (de) *	1996-05-31	2003-04-02	Mochida Pharmaceutical Co., Ltd.	PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
US6217886B1 (en) *	1997-07-14	2001-04-17	The Board Of Trustees Of The University Of Illinois	Materials and methods for making improved micelle compositions
PL345583A1 (en) *	1998-07-20	2001-12-17	Sod Conseils Rech Applic	Peptide analogues of pacap
AU7352200A (en) *	1999-09-01	2001-03-26	Regents Of The University Of California, The	Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
EP1233811A2 (de) *	1999-11-12	2002-08-28	Leo Rubin	Verfahren zur behandlung von herzstillstand oder pulmonarer hypertension und substanzen zur verwendung dafür mit vasoaktivem intestinalen polypeptid und kardiales gerät zur elektrischen und chemischen regulation sowie verwendungsverfahren dafür
AU2072002A (en) *	2000-11-28	2002-06-11	Mondobiotech Sa	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

2003
- 2003-06-05 AU AU2003236072A patent/AU2003236072B2/en not_active Ceased
- 2003-06-05 DK DK03722171T patent/DK1515745T3/da active
- 2003-06-05 BR BR0305039-4A patent/BR0305039A/pt not_active IP Right Cessation
- 2003-06-05 DE DE60326723T patent/DE60326723D1/de not_active Expired - Lifetime
- 2003-06-05 JP JP2004510821A patent/JP2005535607A/ja active Pending
- 2003-06-05 WO PCT/CH2003/000357 patent/WO2003103702A1/en not_active Ceased
- 2003-06-05 CN CNB038134241A patent/CN1313149C/zh not_active Expired - Fee Related
- 2003-06-05 EP EP03722171A patent/EP1515745B1/de not_active Expired - Lifetime
- 2003-06-05 CN CNA200710085571XA patent/CN101015679A/zh active Pending
- 2003-06-05 CA CA002488358A patent/CA2488358A1/en not_active Abandoned
- 2003-06-05 HK HK06100212.6A patent/HK1080363B/zh not_active IP Right Cessation
- 2003-06-05 AT AT03722171T patent/ATE425763T1/de active
- 2003-06-05 US US10/517,125 patent/US20060241028A1/en not_active Abandoned
2004
- 2004-02-03 NO NO20040488A patent/NO330954B1/no not_active IP Right Cessation
2007
- 2007-05-21 US US11/804,780 patent/US7951778B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20080274961A1 (en)	2008-11-06
WO2003103702A1 (en)	2003-12-18
HK1080363A1 (en)	2006-04-28
AU2003236072B2 (en)	2008-10-23
NO20040488L (no)	2004-04-07
BR0305039A (pt)	2004-11-09
DK1515745T3 (da)	2009-07-13
CN101015679A (zh)	2007-08-15
CN1313149C (zh)	2007-05-02
DE60326723D1 (de)	2009-04-30
US7951778B2 (en)	2011-05-31
EP1515745A1 (de)	2005-03-23
HK1080363B (zh)	2007-12-21
JP2005535607A (ja)	2005-11-24
US20060241028A1 (en)	2006-10-26
EP1515745B1 (de)	2009-03-18
AU2003236072A1 (en)	2003-12-22
ATE425763T1 (de)	2009-04-15
CN1658896A (zh)	2005-08-24
CA2488358A1 (en)	2003-12-18

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO330954B1 (no)	2011-08-22	Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose.
WO2002043746A3 (en)	2002-08-08	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
NO20053430L (no)	2005-09-15	Sammensetninger og fremgangsmater for foroket mukosal levering av Y2 reseptor-bindende peptider og fremgangsmater for behandling og forebygging av fedme.
IL208184A0 (en)	2010-12-30	Glp-1, and methods for treating diabetes
JP7530173B2 (ja)	2024-08-07	活性薬剤の経口投与のための製剤
WO2011149964A3 (en)	2012-05-18	Methods for treating or preventing vascular graft failure
CN1917898B (zh)	2011-08-17	用于治疗间质肺部感染的血管活性肠肽的生物活性物质
US20180050079A1 (en)	2018-02-22	Angiotensin peptides in treating marfan syndrome and related disorders
CA2529604A1 (en)	2005-01-20	Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US20050118109A1 (en)	2005-06-02	Method for treating lung diseases associated with ventilation-perfusion mismatches
WO2001070236A8 (en)	2001-12-06	Preventing and/or treating diabetes mellitus
WO2003061680A3 (en)	2003-11-13	Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
CN105828831A (zh)	2016-08-03	新型肽组合物
AU2003201287A1 (en)	2003-09-02	Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
IL266163B1 (en)	2024-03-01	Pharmaceutical composition and method of treating female sexual dysfunctions
HK1183798A (en)	2014-01-10	Methods for treating or preventing vascular graft failure